🇺🇸 FDA
Patent

US 10335466

AADC polynucleotides for the treatment of parkinson's disease

granted A61KA61K35/76A61K38/51

Quick answer

US patent 10335466 (AADC polynucleotides for the treatment of parkinson's disease) held by VOYAGER THERAPEUTICS, INC. expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VOYAGER THERAPEUTICS, INC.
Grant date
Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K35/76, A61K38/51, A61K48/005, A61P